Cocrystal Pharma, Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, COCP reported earnings of -0.19 USD per share (EPS) for Q3 25, beating the estimate of -0.21 USD, resulting in a 11.30% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.17 USD, with revenue projected to reach -- USD, implying an decrease of -10.53% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Cocrystal Pharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cocrystal Pharma, Inc. Common Stock reported EPS of -$0.19, beating estimates by 11.3%, and revenue of $0.00, 0% as expectations.
How did the market react to Cocrystal Pharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- 0%, changed from $1.03 before the earnings release to $1.03 the day after.
When is Cocrystal Pharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Cocrystal Pharma, Inc. Common Stock's next earnings report?
Based on 5
analysts, Cocrystal Pharma, Inc. Common Stock is expected to report EPS of -$0.17 and revenue of -- for Q4 2025.